靶向肿瘤评估与消除策略：医学科学家与泌尿肿瘤学中分子医学的蓬勃发展

Strategies for targeted tumor assessment and elimination: the physician-scientist and the blossoming of molecular medicine in urologic oncology.

作者信息

Koeneman Kenneth S

机构信息

Department of Urologic Surgery, Comprehensive Cancer Center, Center for Prostate Cancer, University of Minnesota, Minneapolis, MN, USA.

出版信息

Urol Oncol. 2006 Mar-Apr;24(2):117-8. doi: 10.1016/j.urolonc.2005.11.032.

DOI:10.1016/j.urolonc.2005.11.032

PMID:16520274

Abstract

To realize its full potential in treating urologic malignancies, molecular medicine in the post-genomic era requires the science of molecular biology to become a great force of change directed to the critical health questions confronting the clinician. The clinician-scientist is the linchpin to convert an exploratory, reactive stance to a predictive and efficacious paradigm in treating urologic malignancies. The explosion of basic and translational discoveries will demand a "systems biology" approach at the fingertips of the future clinician, and realize the dream of proactive and highly adaptable "engineered" response to the very complex "survival" biology of urologic tumors. To arm our clinicians of tomorrow, the physician-scientists of today need resources, time, and a nurturing environment to ask great questions, and, thus, to solve the problem of cancer.

摘要

为了在治疗泌尿系统恶性肿瘤方面充分发挥其潜力，后基因组时代的分子医学需要分子生物学成为一股强大的变革力量，以应对临床医生面临的关键健康问题。临床医生科学家是将治疗泌尿系统恶性肿瘤的探索性、反应性立场转变为预测性和有效范式的关键。基础和转化研究发现的激增将要求未来的临床医生掌握“系统生物学”方法，并实现对泌尿系统肿瘤极其复杂的“生存”生物学做出主动且高度适应性的“工程化”反应的梦想。为了武装我们未来的临床医生，今天的医生科学家需要资源、时间和有利的环境来提出重大问题，从而解决癌症问题。